
    
      Jaktinib Dihydrochloride Monohydrate is a potent inhibitor of JAK1 and JAK2 that demonstrated
      efficacy and safty in preclinical study and safty in a phase 1 in healthy volunteer.This
      phase 2, open-label, multicenter,randomized study evaluated the efficacy and safety of oral
      Jaktinib Dihydrochloride Monohydrate (100 mg bid or 200 mg qd) for the treatment of
      intermediate-risk and high-risk myelofibrosis.
    
  